Device Life of the Tracheoesophageal Voice Prosthesis Revisited.
Voice prosthesis (VP) device life is a limiting factor of tracheoesophageal (TE) voice restoration that drives patient satisfaction, health care costs, and overall burden. Historic data suggest that TE VPs have an average device life of generally 3 to 6 months, but these data are typically derived from small samples using only 1 or 2 devices.



To reexamine current device life in a large, contemporary cancer hospital in the United States that uses a wide assortment of VPs.



This retrospective observational study included 390 laryngectomized patients with a tracheoesophageal puncture (TEP) who had VP management at MD Anderson Cancer Center between July 1, 2003, and December 31, 2013.



Tracheoesophageal voice-related outcomes were: (1) device life duration to VP removal, and (2) treatment-related and prosthetic-related factors influencing device failure. Primary independent variables included treatment history (extent of surgery and radiation history), VP type (indwelling vs nonindwelling, size, specialty features), and reason for removal (leakage, complication, other). Duration was examined using Kaplan-Meier analysis. Disease, treatment, and patient-specific factors were analyzed as predictors of duration.



Overall, 3648 VPs were placed in the 390 patients (median [range] age, 62 [34-92] years). Indwelling prostheses accounted for more than half (56%) of the devices placed (55%, 20-Fr diameter; 33%, 8-mm length). More than two-thirds (69%) of prostheses were removed because of leakage, while the rest were removed for other reasons. Median device life was 61 days for all prostheses. Indwelling and nonindwelling VPs had median device lives of 70 and 38 days, respectively. There was no significant difference between specialty prostheses compared with standard devices (median duration, 61 vs 70 days, respectively). The Provox ActiValve (Atos Medical) had the longest life. Neither radiation therapy nor extent of surgery had a meaningful impact on device life.



Our data suggest that VP duration demonstrates a lower durability than historically reported. This may reflect the intensification of treatment regimens that complicate TEP management in an era of organ preservation; however, further investigation is needed.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
Jan S
JS
Lewin
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
Leah M
LM
Baumgart
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
Martha P
MP
Barrow
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston.
Katherine A
KA
Hutcheson
D000046:Academic Medical Centers; D015331:Cohort Studies; D019544:Equipment Failure Analysis; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007822:Laryngeal Neoplasms / Q000534:rehabilitation / Q000601:surgery; D007825:Laryngectomy / Q000379:methods* / Q000534:rehabilitation; D007831:Larynx, Artificial / Q000009:adverse effects / Q000592:standards*; D008297:Male; D017060:Patient Satisfaction; D011474:Prosthesis Design; D011475:Prosthesis Failure; D016459:Prosthesis-Related Infections / Q000453:epidemiology / Q000503:physiopathology; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors; D014481:United States; D014833:Voice Quality
Laryngoscope. 2010 Jun;120(6):1135-43
20513030
Otolaryngol Head Neck Surg. 2012 Mar;146(3):395-402
22166968
Head Neck. 2005 Jun;27(6):471-7
15825199
Laryngoscope. 2014 Jul;124(7):1585-91
24352975
Laryngoscope. 1998 Oct;108(10):1561-5
9778302
Laryngoscope. 2008 Feb;118(2):252-7
18090869
Eur Arch Otorhinolaryngol. 2013 Mar;270(4):1447-53
22941391
Laryngoscope. 2011 Apr;121(4):769-76
21381042
Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):167-73
10037283
Laryngorhinootologie. 2006 Dec;85(12):893-6
16612757
Head Neck. 2006 Feb;28(2):142-9
16302192
Arch Otolaryngol Head Neck Surg. 2012 Sep;138(9):833-9
22911245
Med J Armed Forces India. 2007 Jan;63(1):15-8
27407929
Eur Arch Otorhinolaryngol. 2014 Jan;271(1):133-40
23812585
J Laryngol Otol. 2003 Nov;117(11):875-8
14670148
J Cancer Res Ther. 2008 Oct-Dec;4(4):186-91
19052392